Login / Signup

Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.

Aman Chandra KaushikYanjing WangXiangeng WangDong-Qing Wei
Published in: Briefings Bioinform. (2021)
Keyphrases